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Essentials
• The activated partial prothrombin time (aPTT) cannot predict the activity of emicizumab (Emi).
• Adjusted clot waveform analyses using a prothrombin time (PT)/aPTT initiator were developed.
• Activity of Emi in the co-presence of factor VIII or bypassing agents was quantified.
• This assay is useful for assessing coagulation potential in Emi-treated hemophilia A.
Summary. Background:
Emicizumab is an anti-activated factor IX/FX bispecific antibody that mimics activated FVIII cofactor function. Emicizumab does not require activation by thrombin, and its effect on shortening the activated partial thromboplastin time (APTT) is much greater than that of FVIII. Therefore, the APTT has limited utility in hemophilia A (HA) patients treated with emicizumab. Aim: To evaluate the global coagulation potential of emicizumab. Methods: Clot waveform analysis (CWA) with prothrombin time (PT)/APTT mixed reagents was used to define hemostatic monitoring protocols in HA patients. A modified parameter, adjusted-| min1| (Ad|min1|), was developed. Maximum and minimum percentage transmittance were defined as 100% and 0% in the precoagulation and postcoagulation phases, respectively. Ad|min1| was calculated as an index of the maximum velocity of the coagulation process. Results:
Ad|min1| obtained with mixed-trigger reagent (PT/APTT/ buffer, 1 : 15 : 135) in the presence of emicizumab optimally corresponded to the conversion rate estimated in animals; 0.2-0.4 IU dL À1 equivalent FVIII per 1 lg mL À1 emicizumab). Ex vivo addition of emicizumab to HA plasma with or without inhibitors resulted in concentration-dependent increases in Ad|min1|, with some individual variations. The addition of various concentrations of FVIII to HA plasma mixed with emicizumab resulted in dose-dependent increases in Ad|min1|. Similarly, mixtures of activated prothrombin complex concentrate and emicizumab added to HA plasma resulted in dose-dependent increases in Ad|min1|. In contrast, enhanced coagulation potential appeared to be better defined by the clot time than by Ad|min1| in experiments using recombinant activated FVII. Conclusion: The PT/
Introduction
Hemophilia A (HA), which results from a deficiency or defect of factor VIII procoagulant protein, is the most common of the severe bleeding disorders. The development of regular prophylaxis with FVIII products has dramatically improved the quality of life of these patients [1] . Some serious concerns remain, however, regarding the current therapeutic protocols. Frequent intravenous infusions of FVIII products often pose a mental and physical burden, especially for pediatric patients and their parents [2, 3] . Moreover, the development of anti-FVIII antibodies (inhibitors) can seriously complicate clinical management. FVIII inhibitors render standard FVIII treatment ineffective, and make the appropriate hemostatic treatment difficult to determine for these patients [4, 5] . The introduction of the novel humanized mAb emicizumab, which supplements FVIII-related mechanisms irrespective of the presence of FVIII inhibitors, is administered subcutaneously, and has a long-half life, therefore represents a major advance in the treatment of HA patients [6, 7] . Emicizumab (also called ACE910) is a humanized, bispecific antibody against activated FIX (FIXa) and FX that mimics the cofactor function of activated FVIII (FVIIIa) by spatially relocating FIXa and FX to the appropriate position in the tenase complex [6, 7] . In a first-in-patient phase 1 study in HA patients, once-weekly subcutaneous administration of emicizumab for 12 weeks was shown to be well tolerated and substantially effective in preventing bleeding episodes irrespective of the presence of inhibitors [8] . Additionally, the long-term efficacy and safety was confirmed by its extension study [9] . More recently, the effectiveness of emicizumab has been again confirmed by a global clinical phase 3 study of HA patients with FVIII inhibitors [10] . Emicizumab, unlike FVIII, mimics FVIIIa and does not require activation by thrombin [6] , and the shortening effect of the antibody on the activated partial thromboplastin time (APTT) is much greater than that of FVIII [8, 9, 11] .
Current phase 1/2 extension and phase 3 clinical trials have demonstrated that bleeding rates are remarkably reduced by emicizumab prophylaxis [8] [9] [10] . Therefore, hemostatic monitoring may not be required in these circumstances if bleeding is well protected against. Hemostatic monitoring should be considered, however, in the presence of an increased bleeding rate. In such cases, changes in antibody concentration mediated by weight gain or the development of anti-drug antibodies should also be ruled out. In addition, clotting function should be assessed comprehensively when treatment for breakthrough bleeding is required. In such instances, hemostasis should be evaluated in the presence of bypassing agents or FVIII concentrates and emicizumab. Standard APTT results are markedly shortened in the presence of small amounts of emicizumab [8, 9, 11] . Conventional APTT assays may therefore not reflect in vivo clotting function, and may not be useful for monitoring emicizumab-treated HA patients. Global tests of clotting function may be more appropriate.
In this respect, clot waveform analysis (CWA) is a recently developed technique based on the continuous observation of changes in light transmittance that occur as fibrin is formed during the performance of routine clotting tests, including the APTT and prothrombin time (PT) [12] . Recommendations on the standardization and clinical application of CWA have recently been published [13] . We have reported some advantages of CWA in HA patients with or without inhibitors [14] [15] [16] [17] . APTT-based CWA patterns obtained with a standard reference based on recombinant FVIII (rFVIII) demonstrated that the lowest level of sensitivity was an FVIII activity (FVIII:C) of 0.2 IU dL À1 [15, 16] . Furthermore, a different coagulation potential was evident in HA patients with similar levels of FVIII measured with one-stage clotting assays, and CWA appeared to reflect clinical severity more consistently than conventional assays [14, 17] . In addition, the use of a trigger reagent comprising a balanced mixture of ellagic acid (Elg) and tissue factor (TF), to reflect both intrinsic and extrinsic coagulation activities, provided promising data for the quantitative hemostatic assessment of bypassing therapy, including recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (aPCCs), in HA patients with inhibitors [18] .
In the present study, we have optimized this technique for assessing coagulation potential in HA patients treated with emicizumab, especially in conjunction with other therapeutic products, including FVIII concentrates or bypassing agents utilized for breakthrough bleeding.
Materials and methods

This study was approved by the Medical Research Ethics
Committee of Nara Medical University and Chugai Pharmaceutical Co.
Reagents
Recombinant emicizumab, an IgG 4 mAb, was produced by use of a Chinese hamster ovary cell line [6, 19] . A plasma-derived FVIII (pdFVIII) (CrossEight M; Japan Blood Products Organization, Tokyo, Japan), two types of rFVIII (Kogenate FS [Bayer Japan, Osaka, Japan] and Advate [Baxalta Japan, Tokyo, Japan]), rFVIIa (NovoSeven; Novo Nordisk, Bagsvaerd, Denmark), aPCC (FEIBA; Baxalta Japan) and FVIII-deficient plasma (George-King, Overland Park, KS, USA) were purchased from the indicated vendors. PT reagent (Revohem PT; Sysmex Corporation; Kobe, Japan) and APTT reagent (Thrombocheck APTT-SLA; Sysmex), used as sources of TF and Elg, respectively, were mixed at various ratios.
Plasma samples
All blood samples were obtained after informed consent had been obtained, following local ethical guidelines. None of the study subjects had taken medication that may have inadvertently affected coagulation. Samples were obtained from severe HA patients without inhibitors (n = 5; FVIII:C < 0.2 IU dL
À1
) and patients with inhibitors (n = 9; 2.5-145 BU mL À1 ). Normal plasma was prepared from 30 normal healthy individuals. Blood was collected into plastic tubes containing 3.2% sodium citrate (109 mM; Fuso, Osaka, Japan) at a 9 : 1 ratio. Platelet-poor plasma was obtained after centrifugation of citrated whole blood for 15 min at 1500 9 g. All plasma samples were stored at À 80°C, and were thawed at 37°C immediately prior to the assays. All samples were analyzed within 6 months.
Adjusted CWA
The modified CWA was performed on the CS-2000i (Sysmex) instrument with a trigger reagent comprising an optimized mixture of TF (PT extrinsic activity) and Elg (APTT intrinsic activity) [17] . Measurements were obtained on FVIII-deficient plasma incubated with FVIII or bypassing agents in the presence of various concentrations of emicizumab. Briefly, plasma samples (50 lL) were dispensed into the cuvette, and then preincubated for 3 min with PT and APTT trigger reagent (50 lL) to ensure adequate activation of the contact clotting factors such as prekallikrein, high molecular weight kininogen, FXII, and FXI. CaCl 2 (50 lL) was then added to initiate coagulation. The automated coagulation analyzer detected transmitted light intensity, and the resulting clot waveforms obtained were computer-processed with the commercial kinetic algorithm. A representative clot waveform is shown in Fig. 1A (left panel). The horizontal axis shows the time (t) and the vertical axis shows the transmitted light intensity (T) from the precoagulation phase to the postcoagulation phase. With the traditional CWA technique, maximum (100%) and minimum (0%) transmittance were defined in the precoagulation phase. It is known that baseline transmittance is influenced by interfering substances, including chyle, hemoglobin, and bilirubin, and that transmittance immediately postcoagulation is influenced by fibrinogen concentration and fibrin clot density. The clot time (CT) was determined as the time to the point when the transmittance decreased to a predefined level. The first derivative of the transmittance (dT/ dt) reflected the coagulation velocity at each time point. The minimum value of the first derivative (min1) was calculated as an indicator of the maximum velocity of coagulation achieved. As min1 was derived from negative changes, the data were expressed as |min1| (Fig. 1A , right panel). With the modified CWA, the minimum transmittance (0%) was set in the immediate postcoagulation phase (Fig. 1B , left panel), and Ad|min1| was defined accordingly as the maximum coagulation velocity obtained in the first derivative of this adjusted clot waveform (Fig. 1B , right panel).
Data analysis
Data analysis was performed with Microsoft Excel software. The coefficient of variation (CV) of adjusted CWA was calculated with the formula CV (%) = standard deviation/average value 9 100. The intra-assay CVs were calculated from 10 consecutive measurements with FVIII-deficient plasma incubated with the indicated concentrations of emicizumab (0-300 lg mL À1 ). The interassay CVs were calculated from five daily means of five results per day.
Results
Adjusted CWA with emicizumab CWA has recently been developed to evaluate low FVIII: C levels and the effects of hemostatic treatment with FVIII products and bypassing agents [15, 16, 18] . The principle of the technique is based on dynamic changes in light transmittance caused by fibrin formation, and specific concentrations of individual clotting factors other than FVIII potentially affect the CWA parameters. In this context, large differences in transmittance were observed, especially depending on the fibrinogen concentration in plasma samples, resulting in variations of |min1| (data not shown). Traditional CWA was performed on different batches of FVIII-deficient plasmas in the presence of various concentrations of either rFVIII or emicizumab (Fig. 2Aa,b ). In these experiments, an initial mixture of the PT and APTT activators (PT/APTT/buffer, 1 : 15 : 135) was used as a trigger reagent. The resulting clot waveforms demonstrated that the differences in |min1| calculated from the first derivative (dT/dt) curves and representing coagulation velocity were very small. In addition, dosedependent improvements of |min1| mediated by the addition of FVIII or emicizumab were significantly different between difference batches of FVIII-deficient plasma ( Fig. 2A , right panels). The measurement of individual clotting factors in the two samples (Lot A and Lot B) demonstrated that most were similar, but fibrinogen levels were different by approximately two-fold (data not shown). Therefore, to examine the possible impact of other components involved in fibrin generation, we adjusted the minimum transmittance in the clot waveform to 0% in the immediate postcoagulation phase. The |min1| obtained in this adjusted CWA was redefined as Ad|min1| (Fig. 1B) . In contrast to the traditional CWA, the ranges of Ad|min1| obtained at different concentrations of FVIII or emicizumab were wide (Fig. 2Ba,b) , and the dose-related improvements in Ad|min1| were similar between different batches of FVIII-deficient plasma (Fig. 2B, right panels) . It therefore seemed likely that elimination of the impact of fibrinogen concentration on the Ad|min1| parameter had a major effect on the differences shown in Fig. 2 , and these results suggested that the Ad|min1| parameter in adjusted CWA could be more useful than the traditional |min1| for assessing the efficacy of emicizumab.
Optimization of the trigger reagent for adjusted CWA Unlike FVIII, emicizumab does not require activation by thrombin, and mediates marked shortening of the APTT [6, 8, 9] . A reagent activating both extrinsic and intrinsic coagulation could therefore be useful for monitoring emicizumab-related coagulation. In addition, a mixed trigger reagent of this type, containing, for example, TF and Elg, could improve the hemostatic assessment of bypassing therapy in inhibitor patients. Furthermore, reliable, easy-to-use CWA procedures using commercially available PT and APTT reagents as sources of TF and El could offer advantages in laboratories other than specialized centers. We therefore extended our investigations, using mixtures of readily available PT and APTT reagents. (Fig. 3A) . In these instances, PT concentration-dependent increases in Ad|min1| were evident at low concentrations of emicizumab (10 lg mL
À1
; Fig. 3Aa ) and in the absence of FVIII (Fig. 3Ab ), but were not apparent at higher concentrations of emicizumab and FVIII. Moreover, the emicizumab and FVIII concentration-dependent increases in Ad|min1| appeared to be most striking at the lower concentrations of PT.
Similar experiments were then repeated with trigger reagents containing a constant concentration of PT reagent with various concentrations of APTT reagent (PT/APTT/buffer, 1 : 1 : 149, 1 : 4 : 146, 1 : 15 : 135, and 1 : 50 : 100) (Fig. 3B) . These results demonstrated that APTT concentration-dependent increases in Ad|min1| were related to the concentrations of emicizumab (Fig. 3Ba) and FVIII (Fig. 3Bb) . However, insignificant increases in Ad|min1| were observed at an equal ratio of PT reagent and APTT reagent. In addition, the activity of emicizumab added to FVIII-deficient plasma, equivalent to that mediated by FVIII:C in the absence of the mAb, was plotted as a function of emicizumab concentration (Fig. 3A,Bc) . On the basis of an estimated conversion rate of 0.2-0.4 IU dL À1 equivalent FVIII per 1 lg mL À1 emicizumab (dashed lines) reported in an earlier animal model [20] , an optimum trigger reagent was defined for use in modified CWA (PT/APTT/buffer, 1 : 15 : 135).
Intra-assay and interassay reproducibility in PT/APTT-based adjusted CWA
Within-run and between-day reproducibility of the optimized assay was assessed with emicizumab (0-300 lg mL À1 ) mixed with FVIII-deficient plasma and incubated with the newly defined trigger reagent. Intraassay and interassay CVs are summarized in Table 1 for CT, and 0.35-1.16% and 0.41-1.67% for Ad|min1|, respectively. In addition, the CV was < 5% even in the absence or presence of low concentrations of emicizumab Adjusted CWA in plasmas from HA patients incubated with emicizumab
The coagulant effects of emicizumab in plasma from HA patients without or with inhibitors were assessed with modified CWA. Ad|min1| was analyzed on individual plasma samples from five HA patients without inhibitors (FVIII:C < 1 IU dL À1 ; Fig. 4A ) and nine HA patients with inhibitors (2.5-145 BU mL À1 ; Fig. 4B ) after the addition of various concentrations of emicizumab. Significant, dose-dependent increases in Ad|min1| were demonstrated, irrespective of the presence of inhibitors, although some individual variations were observed. In particular, Ad|min1| calculations were markedly improved in all cases at emicizumab concentrations of 30 lg mL
and 100 lg mL À1 , corresponding to plasma trough levels in the C2 and C3 cohorts of the Japanese clinical phase 1/2 extension study [8, 9] . Moreover, Ad|min1| remained below the levels of that obtained in 30 normal healthy individuals (7.98 AE 0.24), even at the highest concentrations of emicizumab employed (300 lg mL À1 ), suggesting that the coagulation potential mediated by emicizumab therapy alone might not reach that of a healthy individual.
Adjusted CWA in the presence of emicizumab and FVIII or bypassing agents FVIII concentrates and bypassing agents (rFVIIa and aPCC) are commonly accepted for first-line treatment in HA patients without or with inhibitors, respectively. More recently, emicizumab has been utilized for Adjusted-|min1| (Ad|min1|) was derived from adjusted clot waveforms in all instances. All experiments were performed on at least three separate occasions, and the average values and standard deviation were calculated. The variability of the assays was very low, reflecting the high sensitivity of the techniques. Consequently, the bars for standard deviation were shorter than the symbols, and were difficult to illustrate. Ad|min1| values were plotted as a function of emicizumab (a) or FVIII (b) concentration, and the estimated FVIII levels were plotted as a function of emicizumab concentration (c). The broken lines show the estimated conversion rates based on 0.2-0.4 IU dL À1 equivalent FVIII per 1 lg mL À1 emicizumab previously reported in an animal model [20] .
prophylactic treatment to reduce or prevent bleeds in these HA patients. We therefore examined the potential use of CWA for monitoring therapy during breakthrough bleeds in such patients. We first investigated whether the Ad|min1| parameter in adjusted CWA could provide a useful index of coagulation potential in HA patients in the presence of FVIII and emicizumab. Various concentrations of FVIII agents (1, 5, 20, 40 , 100 and 200 IU dL À1 ) were incubated with different concentrations of emicizumab (0, 30, 100, and 300 lg mL
) and then added to FVIII-deficient plasma prior to adjusted PT/APTT reagent-triggered CWA. FVIII dose-dependent increases in Ad|min1| were observed at all concentrations of emicizumab, and were similar with pdFVIII and rFVIII (Fig. 5) . Ad|min1| increased gradually in the presence of FVIII (20- ) incubated with emicizumab appeared to mediate coagulant activity beyond that observed in normal plasmas, although the Ad|min1| measurements converged with sequential increases in FVIII and emicizumab levels.
Similar experiments were repeated with FVIII-bypassing agents with emicizumab. The presence of rFVIIa enhanced Ad|min1| in the presence of emicizumab, but the improvements did not appear to be dose-dependent, and were less than those with normal plasmas. Moreover, the increases were saturable (Ad|mim1|:~6) at 100 lg mL À1 emicizumab and concentrations of rFVIIa above approximately 2-6 lg mL À1 (corresponding to 90 lg kg
and 270 lg kg
in clinical practice) Ad|min1|, adjusted-|min1|; CT, clot time; max., maximum; min., minimum. This table shows ( Fig. 6Aa) . In contrast, dose-dependent increases in Ad| min1| were evident with aPCC added to plasma samples with emicizumab. Ad|min1| measurements were dosedependently close to but not beyond the levels in normal plasmas in the presence of aPCC (0.5, 1 and 2 IU mL À1 , corresponding to 40, 80 and 160 IU kg À1 , respectively, used for clinical administration) and emicizumab (100 lg mL À1 ) (Fig. 6Ab) . In these experiments, the effects of bypassing agents were also assessed by use of the CT. With this parameter, both rFVIIa and aPCC increased the emicizumab-related activity with a shorter CT dose-dependently as the additive effects (Fig. 6Ba,b) . The CT converged with sequential increases in bypassing agents and emicizumab levels beyond the levels in normal plasma. These differences between Ad|min1| and the CT indicated that rFVIIa and aPCC had different modes of action. Overall, these findings demonstrated that PT/ APTT trigger reagent-adjusted CWA could provide a simple means for hemostatic monitoring of the coagulant activity of emicizumab in the absence or presence of FVIII or FVIII-bypassing agent.
Discussion
The APTT measures the transition from procoagulation to activated coagulation and fibrin formation. Emicizumab mimics the cofactor function of FVIIIa [8, 9, 11] , and markedly shortens the APTT. The coagulation activity of emicizumab has been investigated in basic research and in clinical trials using thrombin generation assays [6, 8, 9] . This type of assay is not widely utilized, however, and appears to be complicated, with limited versatility. TF-triggered coagulation function reflects the modern concept of a cell-based coagulation model [21] , and our previous studies demonstrated that CWA, triggered by a TF/Elg mixture, was useful for monitoring hemostasis in HA patients with inhibitors treated with FVIII-bypassing agents [18] . The present investigation was therefore designed to examine the use of CWA as an easy-to-use procedure for monitoring the FVIII-mimicking effect of emicizumab, using a diluted mixture of commercially available PT and APTT reagents. The mixed trigger was established to reflect both the extrinsic and intrinsic coagulation pathways through initiation by activated FVII (FVIIa)/TF (PT) and consolidation of subsequent FVIIIrelated APTT reactions with high sensitivity. Furthermore, to minimize the influence of fibrinogen as a variable adversely affecting CWA data, analysis of the waveform was modified by reassessing the definition of percentage transmittance to provide an adjusted parameter (Ad|min1|). Ad|min1| was calculated as the maximum velocity of the coagulation process by employing the modified percentage transmittance. This modification increased the sensitivity of the data and reduced the differences between sample batches.
Emicizumab does not moderate FVIII:C, but the antibody has a weaker affinity than FVIII for FIXa and FX [6, 7] , and it was difficult to evaluate coagulation potential in the presence of both emicizumab and FVIII. The Ad| min1| parameter in modified CWA, however, appeared to quantify the complex inter-reactions of these factors in the clotting mechanism. We demonstrated that spiking The concentrations of emicizumab used were as follows; 0 lg mL À1 , circles; 30 lg mL
À1
, triangles; 100 lg mL
, squares; and 300 lg mL
, diamonds. All experiments were performed on at least three separate occasions, and the average values and standard deviation (SD) are shown. The gray bar represents the reference range (7.98 AE 0.24; average AE SD) of Ad|min1| obtained with 30 control normal plasmas (NPs). Emi, emicizumab; pd, platelet-derived; r, recombinant.
FVIII-deficient plasma with different concentrations of FVIII dose-dependently increased Ad|min1|, and that different batches of FVIII products added to the same FVIII-deficient plasma gave similar |min1| results at specific concentrations of FVIII (data not shown). We have also performed similar experiments with FIX-deficient plasma spiked with various concentrations of FIX, and, as was found with FVIII, different concentrations of FIX caused dose-dependent increases in Ad|min1| (Nogami and Matsumoto, unpublished data) . These data are included in a new manuscript on PT/APTT-based CWA in various clotting factor-deficient plasmas (in preparation). In addition, our data indicated that adjusted CWA could be clinically informative in the presence of breakthrough bleeds requiring intensive therapy with FVIII concentrates together with emicizumab.
Our results also suggested that the modified CWA measurements reflected diverse additive effects on enhanced coagulation potential with the two different FVIIIbypassing agents in the presence of emicizumab in HA patients with inhibitors. In mixtures of rFVIIa and emicizumab, the Ad|min1| parameter appeared to provide a relatively poor index of activity, and the additive effects of the activated clotting factor were not dose-dependent. It therefore appeared to be difficult to evaluate the quantitative effect of rFVIIa in the presence of emicizumab. Conversely, the CT was significantly shortened by the presence of rFVIIa. These results were in keeping with the understanding that the primary activity of rFVIIa is attributable to activation of the initiation phase of coagulation, with limited effects on the intrinsic coagulation process involving the propagation and amplification phases [22] . In contrast, in mixtures of aPCC and emicizumab, Ad|min1| was increased and the CT was decreased dose-dependently by the bypassing agent, although the coagulation potential at clinically used concentrations of aPCC (0.5-2.0 IU mL À1 [23] ) with emicizumab (100 lg mL
) remained below that of normal plasma. aPCC contains a mixture of clotting components, including FII, FVII(a), FIX(a), and FX/activated FX [23] , and could be expected to amplify the potential of emicizumab following FVIIa-induced activation of the initiation phase by supplementing FIXa-mediated and FX-mediated intrinsic coagulation reactions. The findings were therefore consistent with the different modes of action of the FVIII-bypassing reagents.
Significant differences in Ad|min1| were observed with some HA plasma samples, especially in the absence of emicizumab. The results suggested that the CWA data reflected the heterogeneity of endogenous coagulation potential in individual patients. The addition of emicizumab, however, improved coagulability to a similar extent in all cases. Earlier studies have identified, by the use of one-stage clotting assays and chromogenic assays, discrepancies in FVIII:C levels associated with genetic mutations [24] , and we have previously suggested that a combination of global coagulation assays could lead to clarification of the clinical phenotype in HA patients [25, 26] . Our present findings indicated that initial assessment of individual HA patients by the use of CWA prior to administration of emicizumab could therefore provide valuable details for patient-specific therapeutic doses of emicizumab and FVIII. The Ad|min1| parameter probably reflects the activity of FVIIIa rather than FVIII in the propagation and amplification processes of coagulation, however, and this assay could be particularly suitable for non-severe HA patients treated with emicizumab. Further investigations of the coagulant effect of emicizumab in non-severe HA patients are in progress.
Some limitations of the technique remain to be considered, however. Equivalent FVIII:C levels appeared to correspond to the optimum conversion rates estimated in in vivo animal studies, but this correspondence probably depended on the type and severity of injury, and could be very different in humans. Nevertheless, previous clinical studies demonstrated that bleeding rates were remarkably reduced by emicizumab prophylaxis in HA patients [8] [9] [10] . Furthermore, in the presence of TF as a CWA trigger, the CTs of plasmas from HA patients were shorter than with the conventional APTT, and the differences may be difficult to interpret at low concentrations of FVIII in HA patients in the presence of emicizumab. Also, the results in this study were based on Elg as the APTT trigger reagent, and we did not consider other intrinsic activators, such as silica-based reagents. The contribution of clotting factors other than FVIII to Ad|min1| requires further clarification, and the use of PT and APTT reagents other than TF and Elg also deserves consideration. Nevertheless, CWA is a reproducible, versatile, economical and readily available technique, and, in addition to studies of HA, we have reported the usefulness of mixture-triggered CWA for assessing the enhancing hemostatic effect of emicizumab in plasma from FXI-deficient patients [27] . The use of commercially available reagents has the potential for application in routine hemostasis laboratories, and wider in vivo studies in patients treated with emicizumab appear to be warranted.
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